Study Details

Back to Search Results

Long-term study of FK949E in elderly bipolar disorder patients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01737268

Astellas Study ID

The unique identification code given by the study sponsor.

6949-CL-0022

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Bipolar Disorder/Depression, Bipolar Disorder/Depression (Elderly)

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

65 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Oct 2012 - Jun 2016

Masking

None (Open Label)

Enrollment number

20

Long-term Study of FK949E in Elderly Patients –Long-term Study in Elderly Bipolar Disorder Patients with Major Depressive Episodes–

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Long-term study of FK949E in elderly bipolar disorder patients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00030

Tottori, Japan

Site JP00013

Hokkaido, Japan

Site JP00019

Kumamoto, Japan

Site JP00018

Kyoto, Japan

Site JP00012

Hokkaido, Japan

Site JP00021

Tokyo, Japan

Site JP00023

Fukuoka, Japan

Site JP00010

Hokkaido, Japan

Site JP00007

Hokkaido, Japan

Site JP00008

Hokkaido, Japan

Site JP00004

Hokkaido, Japan

Site JP00027

Tokyo, Japan

Site JP00006

Hokkaido, Japan

Site JP00031

Ibaraki, Japan

Site JP00022

Tokyo, Japan

Site JP00005

Hokkaido, Japan

Site JP00011

Hokkaido, Japan

Site JP00029

Fukushima, Japan

Site JP00009

Hokkaido, Japan

Site JP00028

Hyogo, Japan

Site JP00002

Hokkaido, Japan

Site JP00032

Kanagawa, Japan

Site JP00003

Hokkaido, Japan

Site JP00020

Tokyo, Japan

Site JP00014

Osaka, Japan

Site JP00016

Tokyo, Japan

Site JP00026

Tokyo, Japan

Site JP00017

Kanagawa, Japan

Site JP00024

Chiba, Japan

Site JP00015

Fukushima, Japan

Site JP00025

Fukuoka, Japan

Site JP00001

Hokkaido, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo